Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Biosimilar> ?p ?o. }
Showing items 1 to 31 of
31
with 100 items per page.
- Biosimilar abstract "Biosimilars also known as follow-on biologics are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods.Biosimilars (or follow-on biologics) are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Biosimilars are also referred to as subsequent entry biologics (SEBs) in Canada. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product. Differences in impurities and/or breakdown products can have serious health implications. This has created a concern that copies of biologics might perform differently than the original branded version of the product. Consequently only a few subsequent versions of biologics have been authorized in the US through the simplified procedures allowed for small molecule generics, namely Menotropins (January 1997) and Enoxaparin (July 2010), and a further eight biologics through the 505(b)(2) pathway.".
- Biosimilar wikiPageExternalLink thomas.loc.gov.
- Biosimilar wikiPageExternalLink whats-keeping-generic-version-biologic-drugs-u-s-market.
- Biosimilar wikiPageID "12924448".
- Biosimilar wikiPageRevisionID "605060362".
- Biosimilar hasPhotoCollection Biosimilar.
- Biosimilar subject Category:Biotechnology.
- Biosimilar subject Category:Drugs.
- Biosimilar type Agent114778436.
- Biosimilar type CausalAgent100007347.
- Biosimilar type Drug103247620.
- Biosimilar type Drugs.
- Biosimilar type Matter100020827.
- Biosimilar type PhysicalEntity100001930.
- Biosimilar type Substance100020090.
- Biosimilar comment "Biosimilars also known as follow-on biologics are biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA or controlled gene expression methods.Biosimilars (or follow-on biologics) are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product.".
- Biosimilar label "Biosimilar".
- Biosimilar label "Biosimilar".
- Biosimilar label "Farmaco biosimilare".
- Biosimilar label "Médicament bio-similaire".
- Biosimilar label "بدائل حيوية".
- Biosimilar sameAs Biosimilar.
- Biosimilar sameAs Médicament_bio-similaire.
- Biosimilar sameAs Farmaco_biosimilare.
- Biosimilar sameAs 동등생물의약품.
- Biosimilar sameAs m.02y__63.
- Biosimilar sameAs Q864715.
- Biosimilar sameAs Q864715.
- Biosimilar sameAs Biosimilar.
- Biosimilar wasDerivedFrom Biosimilar?oldid=605060362.
- Biosimilar isPrimaryTopicOf Biosimilar.